Sep 6, 2019
MediSieve shortlisted for 2019 RSC Emerging Technologies Competition
MediSieve was shortlisted for the final round of 2019 Emerging Technology Competition, run by the Royal Society of Chemistry.
LONDON – September 06, 2019 – The Emerging Technology Competition is held every year and is targeted at early stage companies and academic entrepreneurs who want to commercialise their technologies to make a global impact. This prestigous competition is backed by multinational corporations and one of the world top business school: Cambridge Judge Business School.
The participants are competing within several categories:
• Health
• Energy & environment
• Food & drink
• Enabling technologies
This year MediSieve was announced as a finalist in the health category. We are going to showcase our technology to a panel of judges and live audience during the final on 28 October 2019 at Chemistry Means Business event.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
